PDCD1 and non-small cell lung carcinoma: As such, monoclonal antibodies (mAbs) against PD-1 (e.g. nivolumab and pembrolizumab) or PD-L1 (e.g. atezolizumab) have become one of the standard treatments for patients with advanced or recurrent non-small cell lung cancer (NSCLC).